Current evidence indicates that RCAN1 reduction is beneficial to atherosclerosis, which may have therapeutic potential for slowing or delaying the progression of atherosclerosis by inhibiting CD36 and VEGF signaling. This evidence concerns the gene RCAN1 and atherosclerosis.